Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 2,400 shares at $5.00 ($12K) on 2024-11-11, disclosed to the SEC on 2024-11-13.
Scheduled sale ($12k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |